Shots:
- Teva Pharmaceuticals International secured semi-exclusive marketing rights for FYB203, a biosimilar of Eylea (aflibercept), in Europe (excl. Italy) & Israel via a deal with Klinge & Formycon, boosting Teva’s biosimilar portfolio
- The deal combines Teva’s commercial expertise & distribution network with Formycon’s biosimilar development capabilities, following their successful collaboration on marketing FYB201, a biosimilar of Lucentis (Ranibizumab), in Europe
- As per the terms, Klinge will receive milestones & revenue share in exchange for Teva marketing FYB203 as Ahzantive after EC approval (expected in Jan 2025), while Klinge holds its global commercialization rights
Ref: Globalnewswire | Image: Teva Pharmaceuticals, Klinge Biopharma & Formycon
Related News:- Fresenius Kabi and Formycon Report the CHMP’s Positive Opinion of Ahzantive/Baiama/FYB203 (Biosimilar, Eylea)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
